Prostate cancer imaging by Positron Emission Computed Tomography

Prostate cancer is nowadays a major clinical challenge: it is the most frequently diagnosed cancer in men in Western countries and the second leading cause of cancer death in men over 50 years old. The project objective is to develop a set of integrated solutions for the preparation of best performing prostate imaging radiotracers labelled with Fluorine-18 and Gallium-68. Preclinical and first in human studies will allow ranking these novel tracers and compare them to the current state-of-the art imaging agents. The final ready-to-use solutions will be suitable for routine hospital use, addressing one of the major clinical indication in PET imaging.


Companies: Trasis, Taipro Engineering, Xpress Biologics

Research centers: ULB (CMMI), UZ Leuven

Contact: Jean-Luc Morelle ([email protected]) Trasis